Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

JAMA

Volumn 295, Issue 23, 2006, Pages 2727-2741

  Vogel, Victor G ^a   Costantino, Joseph P ^b,c   Wickerham, D Lawrence ^b,d   Cronin, Walter M ^b   Cecchini, Reena S ^b   Atkins, James N ^e   Bevers, Therese B ^f   Fehrenbacher, Louis ^g   Pajon, Eduardo R ^h   Wade III, James L ⁱ   Robidoux, André ^j   Margolese, Richard G ^k   James, Joan ^l   Lippman, Scott M ^f   Runowicz, Carolyn D ^m   Ganz, Patricia A ⁿ   Reis, Steven E ^o   McCaskill Stevens, Worta ^p   Ford, Leslie G ^p   Jordan, V Craig ^l   Wolmark, Norman ^d   more..

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c NSABP Foundation Inc   (United States)

^d ALLEGHENY GENERAL HOSPITAL   (United States)

^e CCOP   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g KAISER PERMANENTE   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ Central Illinois CCOP   (United States)

^j CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^k MCGILL UNIVERSITY   (Canada)

^l FOX CHASE CANCER CENTER   (United States)

^m UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF PITTSBURGH   (United States)

^p NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CATARACT; CATARACT EXTRACTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; HYPERPLASIA; HYSTERECTOMY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOEMBOLISM; UTERUS CANCER; UTERUS DISEASE;

EID: 33745249570     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.23.joc60074     Document Type: Article

References (51)

1. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res. 2001;61:5683-5687.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
4. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98-101.
5. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824.
6. Veronesi U, Maisonneuve P, Costa A, et al; Italian Tamoxifen Prevention Study. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 1998;352:93-97.
7. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
8. Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol. 2005;23:1644-1655.
9. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987;47:4020-4024.
10. Sporn MB, Dowsett SA, Mershon J, Bryant HU. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Ther. 2004;26:830-840.
11. Lamb CA, Helguero LA, Fabris V, Lucas C, Molinolo AA, Lanari C. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma. Breast Cancer Res Treat. 2003;79:25-35.
12. Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 1990;50:3189-3192.
13. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
14. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial [published correction appears in JAMA. 1999;282:2124]. JAMA. 1999;281:2189-2197.
15. Lippman ME, Krueger KA, Eckert S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants [published correction appears in J Clin Oncol. 2002;20:1430]. J Clin Oncol. 2001;19:3111-3116.
16. Cummings SR, Duong T, Kenyon T, Cauley JA, Whitehead M, Krueger KA; Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 2002;287:216-220.
17. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001;65:125-134.
18. Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
19. Cauley JA, Lucas FL, Kuller LH, et al; Study of Osteoporotic Fractures Research Group. Bone mineral density and risk of breast cancer in older women: The Study of Osteoporotic Fractures. JAMA. 1996;276:1404-1408.
20. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751-1761.
21. Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A. 1997;94:14105-14110.
22. Kleinman D, Karas M, Danilenko M, et al. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology. 1996;137:1089-1095.
23. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol. 1995;9:659-669.
24. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
25. Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst. 2001;93:334-335.
26. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer. 2002;3:153-159.
27. Vogel VG, Costantino JP, Wickerham DL, Cronin WM. National Surgical Adjuvant Breast and Bowel Project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res. 2003;9:495S-501S.
28. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer. 1978;37:849-857.
29. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36), III: tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40-66.
30. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36), II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263.
31. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30:473-483.
32. McHorney CA, Ware JE Jr, Rogers W, Raczek AE, Lu JF. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts: results from the Medical Outcomes Study. Med Care. 1992;30(5 suppl):MS253-MS265.
33. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
34. Sherbourne CD. Social functioning: sexual problems measures. In: Stewart AL, Ware JE, eds. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:194-204.
35. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial [published online ahead of print June 5, 2006]. JAMA. 2006;295:2742-2751. (doi:10.1001/jama.295.23.joc60075).
36. Fleming TR, Harrison DP, O'Brian PC. Designs for group sequential tests. Control Clin Trials. 1984;5:348-361.
37. Korn EL, Dorey FJ. Applications of the crude incidence curves. Stat Med. 1992;11:813-829.
38. Katapodi MC, Lee KA, Facione NC, Dodd MJ. Predictors of perceived breast cancer risk and the relation between perceived risk and breast cancer screening: a meta-analytic review. Prev Med. 2004;38:388-402.
39. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet Gynecol. 2004;104:837-844.
40. Namba R, Young LJ, Maglione JE, et al. Selective estrogen modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ [published online ahead of print September 13, 2005]. Breast Cancer Res. 2005;7:R881-R889 doi:101186/bcr13170. Accessed May 26, 2006.
41. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400-418.
42. Goldman NA, de Los Angeles MM,Jones JG, Goldberg GL. Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene. Obstet Gynecol. 2005;105:1278-1280.
43. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1451.
44. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847-857.
45. Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111:650-656.
46. Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology. 2004;63:1230-1233.
47. Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
48. Wassertheil-Smoller S, Hendrix S, Limacher M, et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
49. Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493-501.
50. Premkumar A, Venzon D, Avila N, et al. Gynecological and hormonal effects of raloxifene in premenopausal subjects at high risk for developing breast cancer [abstract]. AJR Am J Roentgenol. 2006;186(suppl 4):A121.
51. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res. 2004;19:1270-1275.